The granting of certificate follows a proper inspection conducted by the Belgian authorities in May 2011.
With this certification, Ablynx is now eligible to conduct preclinical testing and pharmacokinetics studies in-house, to the required regulatory standard.
Ablynx chairman and CEO Edwin Moses said with this certificate, they no longer solely rely on third parties to carry out the pre-clinical GLP testing for their programmes.
"This enables us to retain more control on quality, timing and associated costs," Moses said.